Community Access Through Remote Eyesight (CARE) Study
CARE
1 other identifier
interventional
145
1 country
2
Brief Summary
Study is a randomized clinical trial evaluating the efficacy of novel mobile application technologies (including Seeing AI, Aira, and Supervision+) to improve quality of life in older adults with low vision by expanding community access and providing assistance with activities of daily living. Aira provides real-time remote personal assistance through a sighted Aira agent supplying direct feedback to assist with visual tasks. Seeing AI provides optical character recognition allowing any text to be read aloud, color identification, bar code reading, scene description, and facial recognition based on stored photos. Supervision + allows one to use the phone as a magnifier, providing magnification and contrast enhancement using the camera of the mobile phone. This study seeks to understand the potential of these technologies to improve daily activities, community participation, independence, and self-sufficiency in this group by examining a technological approach, which has not yet undergone rigorous investigation in a diverse population of older adults with visual impairment. Project objectives are to evaluate mobile applications in a wide range of visual disability, categorized into three groups: (1) mild to moderate visual acuity loss, (2) severe to profound visual acuity loss, and (3) legal blindness secondary to visual field loss. Participants are randomized to one of three intervention groups: (1) Supervision+ application, (2) Aira application, or (3) Seeing AI application for a period of 6 months. For the Aira intervention group, participants will be assigned either with 'restricted' access (current open access areas plus 30 minutes/month anywhere), or 'unrestricted' access (700 minutes), for a period of 3 months with a 3 month cross-over period. Participants may elect to continue the study for an additional 3 months during which time they have access to all 3 study mobile applications. Outcome measures include assessment of changes at three, six and nine months post-intervention for: visual ability, health state (including depression), self-efficacy, loneliness, life space, distances travelled from the home, and types of services obtained.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2021
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 2, 2021
CompletedStudy Start
First participant enrolled
June 2, 2021
CompletedFirst Posted
Study publicly available on registry
June 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 29, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 29, 2023
CompletedOctober 5, 2023
October 1, 2023
2.3 years
June 2, 2021
October 4, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Visual ability change score
The primary outcome measure is the person change score (before and after intervention), from the adaptive Massof Activity Inventory (AI) Questionnaire. The AI has an item bank of 510 items organized into 50 goals and 460 related visually-based tasks. Subscales range from 0 (not important) to 3 (very important). For those goals rated as important, subjects are asked to rate the task difficulty on subscales of 0 (impossible to do without help) to 5 (not difficult). Rasch analysis is employed to estimate visual ability from these difficulty ratings, on an interval scale. With Rasch analysis person measures are estimated, whereby a more positive person measure reflects greater visual ability. In this study, we will explore the the difference in person measures (i.e. change score) after the intervention at 3 and 6 months. A larger, more positive change score indicates greater visual ability since intervention.
AI questionnaire will be administered three times over 6 months: baseline, 3-months post-intervention and 6-months post-intervention, and also 9 months post-intervention
Secondary Outcomes (6)
Health-related Quality of Life: SF-36
will be administered three times over 6 months: baseline, 3-months post-intervention and 6-months post-intervention and also 9 months post-intervention
Beck Depression Inventory
will be administered three times over 6 months: baseline, 3-months post-intervention and 6-months post-intervention and also 9 months post-intervention
Community Living: Life Space Questionnaire
will be administered three times over 6 months: baseline, 3-months post-intervention and 6-months post-intervention and also 9 months post-intervention
3-item UCLA Loneliness Scale
will be administered three times over 6 months: baseline, 3-months post-intervention and 6-months post-intervention and also 9 months post-intervention
New General Self Efficacy Scale
will be administered three times over 6 months: baseline, 3-months post-intervention and 6-months post-intervention and also 9 months post-intervention
- +1 more secondary outcomes
Other Outcomes (3)
Telephone Interview of Cognitive Status (TICS)
administered at time of enrollment
Psychosocial Impact of Assistive Devices Scale (PIADS)
administered at 3-months post-intervention and 6-months post-intervention and also 9 months post-intervention
Aira Explorer Survey post intervention feedback
6 months and also 9 months post-intervention
Study Arms (3)
Seeing AI Smart Phone App
EXPERIMENTALIntervention: Behavioral: Low Vision Rehabilitation
Supervision+ Smart Phone App
EXPERIMENTALIntervention: Behavioral: Low Vision Rehabilitation
Aira Smart Phone App
EXPERIMENTALIntervention: Behavioral: Low Vision Rehabilitation
Interventions
Smart phone App
Eligibility Criteria
You may qualify if:
- age 55 years + (no upper limit)
- reside in CA state (for subjects enrolled at UCLA)
- reside in New England states of MA, NH, CT or RI (for subjects enrolled at NECO)
- best-corrected visual acuity 20/40 to 20/800 in the better eye or visual field diameter less than 20 degrees in the better eye
- English speaking
- Ability to demonstrate proficiency with the smartphone and mobile app at 4 weeks post initial training
- no previous use of the Aira app, Seeing AI app or Super Vision+ app on a smartphone (\<5 uses in lifetime)
You may not qualify if:
- out of the country for \>2 weeks during study intervention period if cannot use their own international data plan on their own phone
- unable to successfully complete the initial on-boarding call for Aira service with an agent as documented by the Aira agent's log (if randomized to Aira)
- schedules not permitting participation in planned study duration (including planning to move or take extended vacation during study period)
- inability to understand study procedures or communicate responses in a consistent manner (cognitive impairment as per TICS)
- substance abuse
- significant hearing loss (unable to hear communication by phone)
- significant medical condition likely to limit participation or lifespan
- participating in another clinical trial that involves treatment that could impact visual function during the study period
- participant in another clinical trial that involves a treatment or intervention that could impact visual functioning
- begins use of a new vision-related app during the trial period for the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
UCLA Stein Eye Institute
Los Angeles, California, 90095, United States
New England College of Optometry
Boston, Massachusetts, 02115, United States
Related Publications (3)
Gobeille M, Bittner AK, Malkin AG, Ho J, Idman-Rait C, Estabrook M, Ross NC; CARE Study Team. Rasch analysis of the new general self efficacy scale: an evaluation of its psychometric properties in older adults with low vision. Health Qual Life Outcomes. 2024 Oct 23;22(1):90. doi: 10.1186/s12955-024-02306-2.
PMID: 39443965DERIVEDBittner AK, Gobeille M, Malkin AG, Ho J, Idman-Rait C, Estabrook M, Ross NC; CARE Study Team. Life space limitations in visually impaired older adults. Optom Vis Sci. 2024 Jun 1;101(6):321-328. doi: 10.1097/OPX.0000000000002150.
PMID: 38990234DERIVEDMalkin AG, Bittner AK, Ho J, Idman-Rait C, Estabrook M, Ross NC; CARE Study Team. Factors related to training time and achieving proficiency with visual-assistive mobile applications in visually impaired older adults. Optom Vis Sci. 2024 Jun 1;101(6):351-357. doi: 10.1097/OPX.0000000000002135. Epub 2024 May 31.
PMID: 38820379DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 2, 2021
First Posted
June 15, 2021
Study Start
June 2, 2021
Primary Completion
September 29, 2023
Study Completion
September 29, 2023
Last Updated
October 5, 2023
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will share
Data will be shared according to the protocols stipulated by NIDILRR and the IRB at NECO and UCLA.